Proshares Trust (ZBIO) Equity Average (2023 - 2025)
Historic Equity Average for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $218.0 million.
- Zenas BioPharma's Equity Average rose 51717.69% to $218.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.0 million, marking a year-over-year increase of 51717.69%. This contributed to the annual value of $43.4 million for FY2024, which is N/A changed from last year.
- Zenas BioPharma's Equity Average amounted to $218.0 million in Q3 2025, which was up 51717.69% from $262.0 million recorded in Q2 2025.
- In the past 5 years, Zenas BioPharma's Equity Average registered a high of $335.9 million during Q4 2024, and its lowest value of -$270.6 million during Q2 2024.
- In the last 3 years, Zenas BioPharma's Equity Average had a median value of $126.7 million in 2024 and averaged $53.2 million.
- Data for Zenas BioPharma's Equity Average shows a peak YoY increase of 51717.69% (in 2025) and a maximum YoY decrease of 19679.76% (in 2025) over the last 5 years.
- Zenas BioPharma's Equity Average (Quarter) stood at -$214.0 million in 2023, then surged by 257.0% to $335.9 million in 2024, then tumbled by 35.1% to $218.0 million in 2025.
- Its Equity Average stands at $218.0 million for Q3 2025, versus $262.0 million for Q2 2025 and $298.4 million for Q1 2025.